FDA Grants 2 Fast Track Designations for ALX148

The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma.

Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news